Who
Rachelle Suzanne Jacques
Director
Company insider
Files Form 4 as: Director, uniQure; Director, Corbus Pharmaceuticals Holdings; Chief Executive Officer, Akari Therapeutics; Director, Viela Bio.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $201K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 5 Apr 2019
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $54K1,993 at $27.06 | filing |
| 11 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $54K1,993 at $27.06 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,550 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,980 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,980 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,550 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $31K2,112 at $14.45 | filing |
| 11 Jun 2025filed 13 Jun 2025 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,630 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,970 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 19 Jun 2024filed 21 Jun 2024 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,840 at $0.00 | filing |
| 19 Jun 2024filed 21 Jun 2024 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —8,080 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $11K2,221 at $5.14 | filing |
| 30 May 2024filed 3 Jun 2024 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —2,783 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,783 at $0.00 | filing |
News
Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)QURE · tickerreport.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastQURE · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Rachelle Suzanne Jacques; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.